1274784-85-8Relevant articles and documents
JAK3 selective inhibitor
-
Paragraph 0019; 0046-0049, (2019/12/25)
The invention discloses a JAK3 selective inhibitor, and relates to a compound represented by formula I/II, or a pharmaceutically acceptable salt thereof. In formula I, Rh, Rg, Rf, m, Re, Rd, Ra, Rb and Rc are as defined in the specification, formula II. The invention also relates to a pharmaceutical composition containing the compound shown in the formula I/II or the pharmaceutically acceptable salt thereof, and applications of the pharmaceutical composition in preparation of drugs for treating inflammation such as rheumatoid arthritis.
Rhodium-catalyzed enantioselective 1,2-addition of arylboronic acids to heteroaryl α-ketoesters for synthesis of heteroaromatic α-hydroxy esters
Wang, Hui,Zhu, Ting-Shun,Xu, Ming-Hua
, p. 9158 - 9164,7 (2012/12/12)
The first example of catalytic asymmetric 1,2-addition of arylboronic acids to heteroaryl α-ketoesters has been developed for the highly efficient and enantioselective synthesis of quaternary carbon-containing heteroaromatic α-hydroxy esters. The reaction works well with a variety of α-ketoesters including 3-indoleglyoxylates, 3-benzofuranglyoxylates and 3-benzothiopheneglyoxylates under very mild conditions, affording the corresponding products in moderate to good yields with high enantiomeric excesses (up to 97%).